JCR aiming for '15 Japanese approval of Prochymal
This article was originally published in Scrip
JCR Pharmaceuticals, Osiris Therapeutics' Japanese partner for Prochymal (remestemcel-L), expects to receive local regulatory approval for the mesenchymal stem cell therapy in 2015, for the indication of graft-versus-host disease (GvHD).
You may also be interested in...
Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.
Also, Osmotica licenses rights to ophthalmic drug in Japan, China and the EMEA nations to Santen; Lilly and Chi-Med revise their partnership around colorectal cancer drug Elunate.
Private Company Edition: Several drug developers targeting neurological diseases raised venture capital recently. In addition to Nura Bio, Encoded Therapeutics revealed a $135m series D round. Also, Longwood closed a $170m fund and Flagship launched Omega Therapeutics with $85m.